Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Oldenburg

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Future Oncology (London, England)|January 16, 2025
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summaryMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
The New England Journal of Medicine|October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial CarcinomaMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
Journal of the National Cancer Institute|June 30, 2010
Testicular cancer survivorship: research strategies and recommendationsLois B Travis, Clair Beard, James M Allan, et al.
European Urology|May 22, 2023
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary FacultyAristotelis Bamias, Arnulf Stenzl, Stephanie L Brown, et al.
European Urology Oncology|July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate CancerSandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
European Urology Oncology|December 27, 2023
A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate CancerFinbar Slevin, Fabio Zattoni, Enrico Checcucci, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Future Oncology (London, England)|January 16, 2025
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summaryMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
The New England Journal of Medicine|October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial CarcinomaMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
Journal of the National Cancer Institute|June 30, 2010
Testicular cancer survivorship: research strategies and recommendationsLois B Travis, Clair Beard, James M Allan, et al.
European Urology|May 22, 2023
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary FacultyAristotelis Bamias, Arnulf Stenzl, Stephanie L Brown, et al.
European Urology Oncology|July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate CancerSandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
European Urology Oncology|December 27, 2023
A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate CancerFinbar Slevin, Fabio Zattoni, Enrico Checcucci, et al.
Pageof 10